Tobacco Cessation; H.R. 6286 Clarifying Authority Over Nicotine Act.
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 5214 - Dietary Supplements Access Act; H.R. 5747 - Dietary Supplement Tax Fairness Act.
OTC and Consumer Products; Oral health; Dietary supplements/DSHEA modernization; Access to over-the-counter medicines; H.R. 5214 - Dietary Supplements Access Act; H.R. 4555 - Oral Health Literacy and Awareness Act; S. 1435/H.R. 2873 - Affordable Prescriptions for Patient Act.
Oral health programs at NIH and CDC.
Medicare coverage of dental care.
Duration: January 1, 2021
to
January 14, 2022
General Issues: Tobacco , Taxation/Internal Revenue Code , Health Issues , Budget/Appropriations , Medicare/Medicaid , Trade (Domestic & Foreign)
Spending: about $170,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), House of Representatives, Health & Human Services - Dept of (HHS), White House Office, Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce - Dept of (DOC), Intl Trade Administration (ITA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2022
Faegre Drinker Biddle & Reath LLP terminated an engagement in which they represented GlaxoSmithKline Consumer Healthcare on April 15, 2022.
Original Filing: 301356750.xml
Lobbying Issues
Tobacco Cessation; H.R. 6286 Clarifying Authority Over Nicotine Act.
Lobbying Issues
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 5214 - Dietary Supplements Access Act; H.R. 5747 - Dietary Supplement Tax Fairness Act.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
OTC and Consumer Products; Oral health; Dietary supplements/DSHEA modernization; Access to over-the-counter medicines; H.R. 5214 - Dietary Supplements Access Act; H.R. 4555 - Oral Health Literacy and Awareness Act; S. 1435/H.R. 2873 - Affordable Prescriptions for Patient Act.
Lobbying Issues
Oral health programs at NIH and CDC.
Lobbying Issues
Medicare coverage of dental care.
4th Quarter, 2021
In Q4, Faegre Drinker Biddle & Reath LLP lobbied for GlaxoSmithKline Consumer Healthcare , earning $40,000. The report was filed on Jan. 11, 2022.
Original Filing: 301321197.xml
Lobbying Issues
Tobacco Cessation; E-cigarette regulation; S. 2622 - Quit Because of COVID Act; H.R. 5546 - PROTECT Act; H.R. 6286 - Clarifying Authority Over Nicotine Act.
Agencies Lobbied
U.S. Senate Centers For Disease Control & Prevention (CDC) Food & Drug Administration (FDA)
Lobbying Issues
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021; H.R. 5214 - Dietary Supplements Access Act; H.R. 5747 - Dietary Supplement Tax Fairness Act; S. 128 - Primary Care Enhancement Act.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021; S. 560 - the Oral Health for Moms Act; FDA; OTC and Consumer Products; Tobacco Cessation; S. 253 - the Cannabidiol and Marihuana Research Expansion Act; H.R. 841 - the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; COVID-19 CDC guidelines for post vaccine pain; Oral health; Dietary supplements/DSHEA modernization; Access to over-the-counter medicines; OTC pain management; S. 2622 - Quit Because of COVID Act; H.R. 5214 - Dietary Supplements Access Act; H.R. 4555 - Oral Health Literacy and Awareness Act; H.R. 379/S. 104 - the Improving Social Determinants of Health Act; S. 1435/H.R. 2873 - Affordable Prescriptions for Patient Act.
Lobbying Issues
Funding for tobacco cessation, chronic disease prevention and health promotion, and oral health programs at NIH and CDC; Funding for VA Headache Centers of Excellence.
Lobbying Issues
Medicare coverage of dental care; S. 560 - the Oral Health for Moms Act; S. 2622 - Quit Because of COVID Act; S. 2618 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2021; S. 3166 - Medicaid Dental Benefit Act.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Faegre Drinker Biddle & Reath LLP lobbied for GlaxoSmithKline Consumer Healthcare , earning $40,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308426.xml
Lobbying Issues
Tobacco Cessation; E-cigarette regulation; S. 2622 - Quit Because of COVID Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Disease Control & Prevention (CDC) Food & Drug Administration (FDA)
Lobbying Issues
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021; H.R. 5214 - Dietary Supplements Access Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021; S. 560 - the Oral Health for Moms Act; FDA; OTC and Consumer Products; Tobacco Cessation; S. 253 - the Cannabidiol and Marihuana Research Expansion Act; H.R. 841 - the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; COVID-19 CDC guidelines for post vaccine pain; Oral health; Dietary supplements/DSHEA modernization; Access to over-the-counter medicines; OTC pain management; S. 2622 - Quit Because of COVID Act; H.R. 5214 - Dietary Supplements Access Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Agency for Healthcare Research & Quality (AHRQ) Centers For Disease Control & Prevention (CDC) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Funding for tobacco cessation and oral health programs at NIH and CDC; Funding for VA Headache Centers of Excellence.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Agency for Healthcare Research & Quality (AHRQ)
Lobbying Issues
Medicare coverage of dental care; S. 560 - the Oral Health for Moms Act; S. 2622 - Quit Because of COVID Act; S. 2618 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Faegre Drinker Biddle & Reath LLP (Formerly Known As Drinker Biddle & Reath LLP) lobbied for GlaxoSmithKline Consumer Healthcare , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301285481.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 295 - the Pandemic Healthcare Access Act; S. 128 - the Primary Care Enhancement Act of 2021; S. 380 - the Health Savings Act of 2021; S. 560 - the Oral Health for Moms Act; FDA; OTC and Consumer Products; Tobacco Cessation; S. 253 - the Cannabidiol and Marihuana Research Expansion Act; H.R. 841 - the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; COVID-19 CDC guidelines for post vaccine pain; Oral health; Dietary supplements/DSHEA modernization; Access to over-the-counter medicines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Agency for Healthcare Research & Quality (AHRQ)
Lobbying Issues
Funding for tobacco cessation and oral health programs at NIH and CDC; Funding for VA Headache Centers of Excellence.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Agency for Healthcare Research & Quality (AHRQ)
Lobbying Issues
Medicare coverage of dental care; S. 560 - the Oral Health for Moms Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Commerce - Dept of (DOC) Intl Trade Administration (ITA)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Faegre Drinker Biddle & Reath LLP (Formerly Known As Drinker Biddle & Reath LLP) lobbied for GlaxoSmithKline Consumer Healthcare , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301263699.xml
Lobbying Issues
Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 295, the Pandemic Healthcare Access Act; S. 128, the Primary Care Enhancement Act of 2021; S. 380, the Health Savings Act of 2021.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 295, the Pandemic Healthcare Access Act; S. 128, the Primary Care Enhancement Act of 2021; S. 380, the Health Savings Act of 2021; S. 560, the Oral Health for Moms Act; FDA; OTC and Consumer Products; Tobacco Cessation; S. 253, the Cannabidiol and Marihuana Research Expansion Act; H.R. 841, the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021.
Lobbying Issues
Funding for tobacco cessation and oral health programs at NIH and CDC.
Lobbying Issues
Medicare coverage of dental care; S. 560, the Oral Health for Moms Act.
1st Quarter, 2021
Faegre Drinker Biddle & Reath LLP filed a lobbying registration on Feb. 4, 2021 to represent GlaxoSmithKline Consumer Healthcare, effective Jan. 1, 2021.
Original Filing: 301247686.xml
Issue(s) they said they’d lobby about: Tobacco cessation; Oral Health; Dietary Supplements; FDA OTC Policy; HSAs/FSAs; Budget: Appropriations for CDC oral health, chronic disease, and tobacco cessation programs. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate